Loading clinical trials...
Loading clinical trials...
An Open Label, Partially Randomised Phase II Study to Investigate the Efficacy and Safety of BIBW 2992 in Patients With Metastatic Colorectal Cancer Who Never Received Prior Anti-EGFR (Epidermal Growth Factor Receptor) Treatment
Conditions
Interventions
BIBW 2992
Cetuximab
Locations
13
United Kingdom
1200.74.44001 Boehringer Ingelheim Investigational Site
Bournemouth, United Kingdom
1200.74.44005 Boehringer Ingelheim Investigational Site
Bristol, United Kingdom
1200.74.44006 Boehringer Ingelheim Investigational Site
Cambridge, United Kingdom
1200.74.44003 Boehringer Ingelheim Investigational Site
Glasgow, United Kingdom
1200.74.44009 Boehringer Ingelheim Investigational Site
London, United Kingdom
1200.74.44012 Boehringer Ingelheim Investigational Site
Manchester, United Kingdom
Start Date
June 1, 2010
Primary Completion Date
March 1, 2012
Last Updated
June 26, 2014
NCT06662786
NCT06663319
NCT05239741
NCT05770102
NCT04812912
NCT06778382
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions